Article

<i>CDKN1B</i> (p27 <sup>kip1</sup> ) enhances drug tolerant persister CTCs by restricting polyploidy following mitotic inhibitors

2024-02-22

Abstract excerpt

<h4>ABSTRACT</h4> The mitotic inhibitor docetaxel (DTX) is often used to treat endocrine-refractory metastatic breast cancer, but initial responses are mitigated as patients eventually have disease progression. Using a cohort of ex vivo cultures of circulating tumor cells (CTCs) from patients with heavily pretreated breast cancer (n=18), we find two distinct patterns of DTX susceptibility, independent of clinica...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3539bbf6-6a75-5cfd-b70b-382dfb584588
DOI: 10.1101/2024.02.20.581202

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

<i>CDKN1B</i> (p27 <sup>kip1</sup> ) enhances drug tolerant persister CTCs by restricting polyploidy following mitotic inhibitorsDOI 10.1101/2024.02.20.581202Read

Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast CancerSemantic proximity Read

Cancer drug-tolerant persister cells: from biological questions to clinical opportunitiesSemantic proximity Read

Drug-tolerant persister cell in cancer: reversibility, microenvironmental interplay, and therapeutic strategiesSemantic proximity Read

Antigenic cancer persister cells survive direct T cell attackSemantic proximity Read

Mechanism of Drug Tolerant Persister Cancer Cells: The Landscape and Clinical Implication for TherapySemantic proximity Read

GPX4-VIM equates a proliferating DTP state in TNBC subtypes with converged vulnerabilities to autophagy and glutathione inhibitionSemantic proximity Read

Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities.Semantic proximity Read

Drug tolerant persister cell plasticity in cancer: a revolutionary strategy for more effective anticancer therapiesSemantic proximity Read

Pharmacological agents targeting drug-tolerant persister cells in cancerSemantic proximity Read

Metabolic orchestration of drug-tolerant persister cells in cancerSemantic proximity Read

Cycling cancer persister cells arise from lineages with distinct transcriptional and metabolic programsSemantic proximity Read

The EGFR inhibitor osimertinib promotes a dynamic Drug Tolerant Persister state marked by replication defects and genome instabilitySemantic proximity Read